Peptides
CJC-1295, Sermorelin, and Ipamorelin Compared
Three peptides studied for growth hormone signaling, three different mechanisms. Here is how CJC-1295, sermorelin, and ipamorelin differ in plain English.
By Toned Team · Reviewed by the Toned editorial team
Published April 22, 2026 · Last reviewed July 7, 2026 · 2 min read
CJC-1295, sermorelin, and ipamorelin are three peptides studied for their effects on growth hormone signaling — but they are not the same thing, and they are not interchangeable. Sermorelin and CJC-1295 nudge the pituitary through the growth-hormone-releasing-hormone pathway; ipamorelin works through a separate receptor as a growth-hormone-secretagogue. Understanding the difference is the point of this guide.
What is sermorelin, the short-acting GHRH analog?
Sermorelin is an analog of growth-hormone-releasing hormone (GHRH). It signals the pituitary to release growth hormone in a pulse that mimics the body's own pattern, then clears quickly. Its short duration is both its appeal — a more natural, pulsatile signal — and its practical limitation.
How does CJC-1295, the longer-acting GHRH analog, differ?
CJC-1295 is also a GHRH analog, but modified to last considerably longer in the body. Research has documented prolonged elevation of growth hormone and IGF-1 signaling compared with shorter-acting compounds. The trade-off is that a longer, flatter signal departs further from the body's natural pulsatile rhythm. CJC-1295 is covered here for education only — it is not part of Toned's offering.
Why does ipamorelin work on a different receptor entirely?
Ipamorelin is not a GHRH analog. It is a selective growth-hormone-secretagogue that acts on the ghrelin/GHS receptor, a separate pathway, which is why it is sometimes discussed alongside a GHRH analog rather than instead of one. It was characterized as one of the first highly selective secretagogues. Toned does not currently offer ipamorelin; it is covered here for education only.
So which one should you use?
None of them without a clinician. These peptides overlap in goal but differ in mechanism, duration, and appropriateness, and human evidence varies across them. Treat this comparison as a map of the landscape, not a recommendation — and if growth hormone signaling is something you want to explore, do it with a licensed provider. For repair-focused peptides discussed in similar circles, see our BPC-157 research overview and the peptide glossary. What Toned prescribes today is compounded GLP-1 medication.
References
- Teichman SL et al. Prolonged stimulation of GH and IGF-I by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006. PubMed
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PubMed
- Hedegaard MA, Holst B. The complex signaling pathways of the ghrelin receptor. Endocrinology. 2020. PubMed
- Abizaid A, Hougland JL. Ghrelin signaling: GOAT and GHS-R1a take a LEAP in complexity. Trends Endocrinol Metab. 2020. PubMed
This article is for general education and is not medical advice. Talk to a licensed provider about your individual situation.